Table 3.
Length of prostacyclin use
| All usage | Usage ≤72 hours | Usage >72 hours | ||||
|---|---|---|---|---|---|---|
| No. | Median (range), days | No. | Median (range), hours | No. | Median (range), days | |
| Total | 35 | 7.0 (0.083–1,332) | 11 | 23.5 (2–72) | 24 | 29.0 (3.6–1,322) |
| CHD | 6 | 14.5 (3.6–1,332) | 1 | 48.0 (NA) | 5 | 415.0 (3.6–1,332) |
| CDH | 8 | 3.3 (0.125–7) | 4 | 10.9 (3–67.2) | 4 | 5.2 (3.8–7) |
| CLD | 9 | 78.0 (0.77–489) | 2 | 34.4 (18.48–50.4) | 7 | 91.0 (23–489) |
| PPHN | 6 | 24.0 (0.7–34) | 2 | 44.4 (0.7–72) | 4 | 30.5 (18–34) |
| Bronchiolitis | 4 | 22.5 (1.94–33) | 1 | 46.6 (NA) | 3 | 33.0 (12–33) |
| Idiopathic PH | 2 | 2.5 (0.98–3.96) | 1 | 23.5 (NA) | 1 | 3.96 (NA) |
Note
CHD: congenital heart disease; CDH: congenital diaphragmatic hernia; CLD: chronic lung disease; PPHN: persistent pulmonary hypertension of the newborn; NA: not applicable; PH: pulmonary hypertension.